Introduction
Vascular endothelial growth factor (VEGF) as a potent angiogenic factor can stimulate capillary formation and enhance cell permeability. [1] [2] [3] Both preclinical and clinical studies have shown that VEGF participated in the pathogenesis of proliferative diabetic retinopathy. [4] [5] [6] Moreover, intraocular VEGF was found increased in the eyes of diabetic patients with blood-retinal barrier breakdown and neovascularization. [4] [5] [6] Notably, inhibition of VEGF activity can prevent neovascularization and blood-retinal barrier breakdown in animal models. [6] [7] [8] [9] Recently, insulin has been reported to increase the expression of VEGF in multiple cell types, including epithelial cells, 10 fibroblasts, 11 and other cells. 12 Moreover, insulin-induced VEGF expression was thought to be associated with the transient worsening of diabetic retinopathy after acute intensive insulin therapy. 10 VEGF is present in various cell types and its expression is regulated by a number of growth factors and cytokines, such as interleukin-1-b, 13 platelet-derived growth factor (PDGF), and transforming growth factor b.
14 PDGF has been reported to stimulate VEGF expression in NIH3T3 fibroblasts in a Ras-and Raf-dependent manner. 15 However, the precise molecular mechanism by which growth factors induce VEGF expression remains poorly understood. Reportedly, insulin-induced VEGF expression was mediated by the activation of phosphatidylinositol 3-kinase/Akt (PI-3K), a downstream element of the insulin receptor. However, almost all the in vitro studies showing an insulinenhanced VEGF expression were conducted under a normal glucose level (5 mM). In fact, the blood glucose level is high in diabetic patients before the initiation of insulin therapy. Therefore, it is of great clinical significance to investigate the VEGF expression in cells exposed to high glucose. This study is aimed at investigating whether insulin can increase VEGF expression in bovine retinal microvascular endothelial cells (BRECs) exposed to higher glucose (30 mM), as it does in those exposed to normal glucose (5 mM), and to preliminarily investigate the related mechanisms.
We used real-time polymerase chain reaction (real-time PCR) to examine the VEGF mRNA expression in BRECs treated with different combinations of insulin and glucose. In vitro proliferation assay of human umbilical vein endothelial cells (HUVECs), immunofluorescence, and ELISA were used to examine the expression of the VEGF protein. To further understand the mechanism underlying the changes of VEGF expression, we also determined the VEGF expression in BRECs pretreated with the inhibitors of PI3-K, and P42/44 mitogenactivated protein kinase (MAPK) and protein kinase C (PKC) pathways before the addition of insulin.
Methods

Cell culture and study design
BRECs were isolated by homogenization and by a series of filtration steps as we described earlier. 16 The cells were subsequently cultured with Dulbecco's modified Eagle's medium supplemented with 10% FBS (GIBCO), 100 mg/l heparin (Sigma), 10 mmol/l HEPES (GIBCO), and 15 mg/l ECGS (Sigma). The culture plate (corning) was coated with Gelatin (Sigma) beforehand. The cells were cultured in 5% CO 2 at 371C and the media were changed every 3 days. Thereafter, the cells were characterized for their homogeneity using an immunoreactivity test with anti-factor VIII antibody for BRECs. 16, 17 Only cells of passages 5-10 were used for this study. Cells were seeded into 60 mm plates (5 Â 10 4 cells/ml, 4 ml) and were incubated with 5 or 30 mM glucose for 3 days.
L-glucose (25 mM) was supplemented to the 5 mM group for osmotic equation. The cells were serum-deprived overnight in Dulbecco's modified Eagle's medium containing 0.2% w/v bovine serum albumin and were then incubated with either 100 nM insulin (Sigma) or not for 24 h. The experiment was therefore divided into four groups: group A (5 mM glucose), group B (5 mM glucose þ 100 nM insulin), group C (30 mM glucose), and group D (30 mM glucose þ 100 nM insulin).
To investigate the mechanisms underlying insulininduced VEGF expression, BRECs were divided into the following five groups: 5 mM glucose þ 100 nM insulin group, 5 mM glucose þ wortmannin þ 100 nM insulin group, 5 mM glucose þ U0126 þ 100 nM insulin group, 5 mM glucose þ GF109203X þ 100 nM insulin group, and 30 mM glucose þ 100 nM insulin group. BRECs were treated with 5 or 30 mM glucose for 3 days; thereafter, the cells cultured with 5 mM glucose were exposed to the PI3-K inhibitor wortmannin (100 nM), to the P42/44 MAPK inhibitor U0126 (50 mM), or to the PKC inhibitor GF109203X (2 mM) (all from Calbiochem, EMD Biosciences, La Jolla, CA) 1 h before the addition of 100 nM insulin. The cells were incubated with insulin for 24 h and then used for real-time PCR and ELISA analyses. 
Proliferation assay of HUVECs
To further understand the VEGF protein expression of each group, the supernatants of each group were used to stimulate the proliferation of HUVECs. HUVECs were isolated from umbilical veins by digestion with collagenase as described earlier. 18 Cells were grown in DMEM supplemented with 10% FBS (GIBCO) and were used between passages 2 and 4. HUVECs were then seeded in 12-well plates (10 4 cells/well). Twenty-four hours later, the media from Group A, B, C, or D were added to the seeded HUVECs. Four days later, the number of cells in each well was determined by two readings with a coulter counter. Each condition was tested in triplicate (mean ± SD, n ¼ 3).
Immunofluorescence detection of the VEGF protein expression
The VEGF protein expression in endothelial cells was detected by an immunofluorescence test. Cultures were fixed with 4% paraformaldehyde and then reacted with an anti-VEGF antibody (Sigma), followed by Oregon green-labeled secondary antibody (Molecular Probes). For negative controls, the primary antibody was omitted.
Examination of the VEGF protein by ELISA
Protein samples of each group were extracted and quantified according to earlier described protocols. 19, 20 In brief, protein samples (50 mg) were added to wells of a 96-well plate coated with VEGF antibody, incubated at 41C overnight, and processed according to the manufacturer's instruction (RayBiotech, Inc, Atlanta, GA, USA). Absorbance was measured in a plate reader at 450 nm. VEGF levels were calculated on the basis of absorbance values by comparing with a standard curve prepared by a six-step serial dilution (from 50 to 3200 pg/ml) of recombinant VEGF. The above experiment was repeated twice.
Statistical analysis
A significance test was carried out using one-way ANOVA, two-way ANOVA, or t-test. A P-value less than 0.05 was deemed to be statistically significant. All analyses were carried out with SAS 6.12 (Statistics Analytical Software; SAS Institute, Cary, North Carolina, USA).
Results
High glucose inhibited insulin-induced VEGF mRNA expression
To determine the effects of high glucose on insulininduced VEGF mRNA expression, serum-starved endothelial cells were treated with 100 nM insulin for 24 h, and VEGF mRNA was quantified by real-time PCR. Both insulin and high glucose significantly increased the VEGF mRNA expression in BRECs, compared with low glucose (Po0.05, two-way ANOVA). However, the combined effect of insulin and high glucose was weaker (Po0.05, t-test) than that with insulin alone (Figure 1 ).
To determine whether there is a peak glucose level that provides the greatest attenuating effect, we conducted the following experiment: BRECs were treated with glucose over a concentration gradient of 5, 10, 15, 20, 25, and 30 mM, before exposure to insulin. The greatest attenuation of VEGF expression was observed in the 25 mM group. However, as shown in Figure 2 ., there was no significant difference between the 25 mM group and the 20 or 30 mM groups.
High glucose attenuated insulin-induced VEGF protein expression
To ascertain whether the change of VEGF mRNA in BRECs in different groups resulted in corresponding changes in the VEGF protein, we analyzed the protein levels of VEGF in the culture supernatant of each group using endothelial cell proliferation assay. The results are expressed as the ratio of VEGF mRNA to b-actin mRNA, Mean ± SD for three separate experiments. *Po0.05 compared with group A, two-way ANOVA; # Po0.05 compared with group B, t-test.
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Eye staining in group A and a strong expression in group B, group C and group D. However, the staining result of the VEGF protein in group D was weaker than that in group B (Figure 3.) . ELISA results showed that the VEGF protein expression in group A was significantly lower than those in groups B (104.14±2.20 vs 58.66±7.62 pg/ ml, respectively, Po0.05, two-way ANOVA), C (105.11 ± 11.14 vs 58.66 ± 7.62 pg/ml, respectively, Po0.05, two-way ANOVA), and D (78.79 ± 4.25 vs 58.66 ± 7.62 pg/ml, respectively, Po0.05, two-way ANOVA). Similarly, The VEGF protein expression in group D was significantly lower than that in group B (78.79±4.25 vs 104.14±2.20 pg/ml, respectively, Po0.05, t-test).
Insulin upregulated VEGF expression in BRECs exposed to 5 mM glucose through PI3-kinase A PI3-kinase inhibitor pretreatment of cells exposed to 5 mM glucose significantly suppressed insulin-induced VEGF mRNA and protein expression (Po0.05, one-way ANOVA). Pretreatment with inhibitors of PKC and P42/p44 MAPK did not show a significant effect on VEGF mRNA and protein expression. Besides, pretreatment of cells with high glucose also significantly suppressed the insulin-induced VEGF mRNA and protein expression (Po0.05, one-way ANOVA). (Figures 4 and 5) . High glucose showed a similar effect as that of the PI3-kinase inhibitor. 5 mM glucose þ 100 nM insulin; group B: 10 mM glucose þ 100 nM insulin; group C: 15 mM glucose þ 100 nM insulin; group D: 20 mM glucose þ 100 nM insulin; group E: 25 mM glucose þ 100 nM insulin; group F: 30 mM glucose þ 100 nM insulin. VEGF mRNA levels were determined by quantitative real-time PCR. The results are expressed as the ratio of VEGF mRNA to b-actin mRNA, mean ± SD for three separate experiments. *Po0.05 compared with group A, one-way ANOVA; # P40.05 compared with group E, one-way ANOVA.
High
Discussion
This study provides experimental evidence that insulin or high glucose can markedly increase VEGF expression at both mRNA and protein levels in BRECs, and the combined effect of insulin and high glucose is weaker than that of insulin alone. We also prove that pretreatment of cells with PI3-K inhibitor can suppress the insulin-induced VEGF expression. Similarly, the pretreatment of cells with high glucose can also suppress the insulin-induced VEGF expression. Therefore, we hypothesize that high glucose may attenuate insulininduced VEGF expression by impairing PI3-K signalling pathways.
The mechanisms underlying the effect of insulin on VEGF expression have been extensively studied. Many studies have shown that the activation of the PI3-K/Akt pathway can upregulate the expression of hypoxiainducible factor-1a (HIF-1a), 10, 11, 21 and subsequently increase VEGF expression by directly interacting with VEGF promoter. 10 Miele C and associates reported that insulin-induced VEGF expression through PI3-K/PKB signalling pathways in NIH3T3 fibroblasts. 11 Some found that insulin-induced VEGF expression was through both PI3-K and P42/44 MAPK pathways in HepG2 cells and in mouse aortic smooth muscle cells. 22, 23 In this study, we found insulin upregulated VEGF in BRECs through PI3-K signalling pathways.
Although high glucose was found to induce VEGF expression in retinal vascular cells by various mechanisms, [24] [25] [26] this study found that the combined effect of high glucose and insulin was weaker than that of insulin alone, suggesting that high glucose inhibited insulin-induced VEGF expression. Through a concentration gradient experiment, we found that the greatest attenuation of VEGF expression was in the 25 mM group, but there was no significant difference between the 25 mM group and the 20 or 30 mM groups. In similar studies, 30 mM is used as a high concentration for glucose. 27, 28 In this study, we also used 30 mM as the highest concentration. Further, we found that, similar to high glucose, the PI3-K inhibitor also inhibited insulininduced VEGF expression, but inhibitors of PKC or P42/ p44 MAPK hardly showed any inhibitory effect against the insulin-induced VEGF expression. Therefore, we assume that high glucose might inhibit insulin-induced VEGF expression through impairing PI3-K signalling pathways. Matthew and associates reported that chronic insulin and high glucose synergistically inhibit the interleukin-4-dependent activation of PI3-kinase in macrophages through the mTOR pathway. 29 Tahir reported that high glucose impaired receptor and insulin receptor substrate-1 phosphorylation by 34%. Phosphatidylinositol 3-kinase activity was decreased by 85%. The impairment of insulin receptor substrate-1 tyrosine phosphorylation is greater than that of the insulin receptor, resulting in attenuated phosphatidylinositol 3-kinase activation and mitogenic signalling. 30 Other studies indicated that high glucose inhibited hypoxia-induced VEGF response in cultured proximal tubular cells at both mRNA and protein levels. 31 Besides, high glucose was also reported to inhibit insulin-stimulated nitric oxide production by impairing molecular (IRS-1, PI 3-kinase) and functional insulin signals in vascular endothelial cells. 32 These findings are consistent with the results of this study that show that high glucose may attenuate insulin-induced VEGF expression by impairing the PI 3-K signalling pathway.
Earlier studies have indicated that insulin-induced VEGF expression was associated with the transient worsening of diabetic retinopathy after acute intensive insulin therapy. 10 However, almost all these in vitro studies, which showed that insulin enhanced VEGF expression, were conducted under a normal glucose level. In fact, the blood glucose level is high in diabetic patients before the initiation of insulin therapy. Our study found that when insulin is administered to high glucose-exposed BRECs, which mimics the real condition of diabetic patients, the expression of VEGF is decreased; hence, we propose that the transient worsening of diabetic retinopathy after insulin therapy is not related to VEGF expression alone. Besides the VEGF increase, other reasons such as insulin-induced intracellular reactive oxygen species (ROS) production and pericyte loss may also be contributing factors. 33 Another study by our group showed that insulin treatment significantly increased intracellular ROS production in BRECs exposed to 30 mM (data not shown). Therefore, we suggest that more efforts should be made to search for other factors that contribute towards the worsening of diabetic retinopathy and the corresponding treatment.
In summary, both insulin and high glucose can markedly increase the VEGF expression in BRECs at the mRNA and protein level. We propose that insulin may upregulate VEGF expression through the PI3-K signalling pathway in BRECs, and high glucose may attenuate insulin-induced VEGF expression by impairing PI3-K signalling pathways. However, further study is necessary to clarify the precise causes of the reduced VEGF expression in the presence of an elevated glucose level.
